It has been announced by pharmaceutical company, Biogen, that Alzheimer’s drug aducanumab (commercially known as Aduhelm) will be withdrawn from use by November 2024. Biogen say this isn’t due to any safety or efficacy concerns.
Aducanumab was offered to people living with Alzheimer’s in the US from June 2021, but was not approved for use in the UK or in Europe.
Biogen have said they plan to, “Reprioritise resources allocated to aducanumab to advance lecanemab and to develop new treatments.” Lecanemab is a newer-generation of Alzheimer’s disease treatment that is subject to a regulatory decision on its use in the UK this year (2024).
You can find out more here: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise